Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL1B | P01584 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.37 |
| ▸ | TSHR | P16473 | 4/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | SRPK2 | P78362 | 1/20 | 0.36 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.36 |
| ▸ | STIM1 | Q13586 | 1/20 | 0.35 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.35 |
| ▸ | USP2 | O75604 | 3/20 | 0.35 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL647018 | 0.93 | IL1B (0.38) | IL1BCYP1A2CYP3A4TSHRCYP2C19 | |
| SCHEMBL647042 | 0.86 | MAPT (0.38) | CYP1A2CYP3A4TSHRCYP2C19ALOX15 | |
| SCHEMBL646781 | 0.83 | STIM1 (0.42) | TSHRSTIM1ORAI1MEN1KMT2A | |
| SCHEMBL647141 | 0.82 | TSHR (0.38) | CYP1A2CYP3A4TSHRCYP2C19ALOX15 | |
| SCHEMBL646766 | 0.82 | MEN1 (0.33) | TSHRSTIM1ORAI1MEN1KMT2A | |
| SCHEMBL648000 | 0.82 | ALOX15 (0.39) | IL1BALOX15PTK2MEN1KMT2A | |
| SCHEMBL649242 | 0.81 | RAB9A (0.38) | SRPK1CLK4MEN1KMT2ANPC1 | |
| SCHEMBL646767 | 0.81 | CYP2C19 (0.44) | CYP1A2CYP3A4TSHRCYP2C19ALOX15 | |
| SCHEMBL647988 | 0.81 | MAPT (0.38) | CYP1A2CYP3A4TSHRCYP2C19ALOX15 | |
| SCHEMBL645748 | 0.80 | MAPT (0.41) | CYP1A2CYP3A4TSHRCYP2C19ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8614321-B2 | Benzoimidazolyl-pyrazine compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2013-12-24 | — | — | US | disclosed |
| US-20120190853-A1 | BENZOIMIDAZOLYL-PYRAZINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120190853-A1 | BENZOIMIDAZOLYL-PYRAZINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120190853-A1 | BENZOIMIDAZOLYL-PYRAZINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2012-07-26 | — | — | US | disclosed |
| US-8119643-B2 | Benzoimidazolyl-pyrazine compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2012-02-21 | — | — | US | disclosed |
| US-8119643-B2 | Benzoimidazolyl-pyrazine compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2012-02-21 | — | — | US | disclosed |
| US-20070249609-A1 | Benzoimidazolyl-pyrazine compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. | 2007-10-25 | — | — | US | disclosed |
| US-20070249609-A1 | Benzoimidazolyl-pyrazine compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190853-A1 | BENZOIMIDAZOLYL-PYRAZINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | IL5, CXCR5, NLRP3 | IL1B 26/4885CYP1A2 1041/4885CYP3A4 549/4885 |
| US-20070249609-A1 | Benzoimidazolyl-pyrazine compounds for inflammation and immune-related uses | IL5, CXCR5, NLRP3 | IL1B 26/4885CYP1A2 1041/4885CYP3A4 549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.